About this trial
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes').
Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area.
Inflammation is the body's natural response to injury or infection. Importantly it is also involved in the development of CAD. Hormones such as oestrogen and testosterone are also likely to be contributory factors. The investigators think the differences between the way these hormones and inflammation play a part in CAD in both men and women are important, but the role they play is not yet fully understood.
In this study the investigators wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. The investigators will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. The investigators will combine this data with the data that is routinely collected during hospital admission. In this way the investigators hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research the investigators will address an under researched area and find new ways of treating women and men with coronary artery disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
All patients attending Barts Heart Centre with chest pain
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Mortality
Mortality at 30 days,1 year and 5 years, and relation to sex hormone/menstrual status/inflammatory profile
Re-admission
Re-admission rates post revascularization and relation to sex hormone/menstrual status/inflammatory profile
MACE
MACE post revascularisation and relation to sex hormone/menstrual status/inflammatory profile
Secondary outcomes
Relationship with specific MI types
Relationship of sex hormone/menstrual status/inflammatory profile with specific types of ACS such as MINOCA
Relationship with inflammation
Relationship of sex hormone/menstrual status with markers of inflammation (e.g white cell count, CRP, D-dimer) and severity of disease (e.g troponin, extent of coronary disease)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.